Coherus Biosciences | CHRS - Sales Revenues


Coherus Biosciences reported $12.75M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
AbbVie USD 16.99B 1.99B Jun/2026
Acadia Pharmaceuticals USD 307.96M 39.9M Jun/2026
Akebia Therapeutics USD 57.62M 1.14M Dec/2025
ALKERMES USD 496.01M 103.1M Jun/2026
Alnylam Pharmaceuticals USD 1.29B 120M Jun/2026
Amarin USD 49.22M 451K Dec/2025
Amgen USD 10.1B 1.48B Jun/2026
Baxter International USD 2.96B 260M Jun/2026
Biogen USD 2.74B 490M Jun/2026
BioMarin Pharmaceutical USD 990M 224M Jun/2026
Bristol-Myers Squibb USD 12.97B 1.48B Jun/2026
Coherus Biosciences USD 12.75M 1.18M Dec/2025
Eli Lilly USD 22.97B 3.17B Jun/2026
Fujifilm JPY 826.49B 100.76B Jun/2026
Gilead Sciences USD 7.8B 800M Jun/2026
Ironwood Pharmaceuticals USD 113.04M 6.53M Jun/2026
Merck USD 16.6B 310M Jun/2026
Myriad Genetics USD 190.7M 9.7M Jun/2026
Pacira USD 192.4M 15.4M Jun/2026
Perrigo USD 1.02B 51M Jun/2026
Pfizer USD 15.03B 530M Jun/2026
PTC Therapeutics USD 361M 88M Jun/2026
Regeneron Pharmaceuticals USD 4.29B 690M Jun/2026
Sarepta Therapeutics USD 401.3M 329.5M Jun/2026
Teva Pharmaceutical Industries USD 12.67B 900M Jun/2026
Vertex Pharmaceuticals USD 3.33B 340M Jun/2026
Xencor USD 51.22M 46.71M Jun/2026
Zoetis USD 2.5B 200M Jun/2026